Skip to main content
. 2022 Jul 15;13:961796. doi: 10.3389/fimmu.2022.961796

Figure 2.

Figure 2

Oncolytic virus combined with immune checkpoint inhibitor in the treatment of colorectal cancer. OVs, lyse tumor cells while attracting immune cells (e.g., CD8+ T cells, NK cells) to the tumor microenvironment, thus transforming a ‘cold’’ tumor into a ‘hot’’ one to enhance the sensitivity of tumor cells to ICIs. In addition, OVs can enhance the targeted therapeutic effect of PD-1/PD-L1 inhibitors by up-regulating the expression of tumor cell immune checkpoint PD-L1.